Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results.
Year: 2014
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Andrew David Norden, Jan Drappatz, Surasak Phuphanich, David A. Reardon, Eric T. Wong, Scott Randall Plotkin, Thomas Joseph Kaley, Jeffrey J. Raizer, Glenn Jay Lesser, Tracy Batchelor, Eudocia Quant Lee, Rameen Beroukhim, Alona Muzikansky, Lisa M. Doherty, Debra C. LaFrankie, Sandra Ruland, Katrina H. Smith, Mary Gerard, Christine Sceppa McCluskey, Patrick Y. Wen
Institutions: Dana-Farber Cancer Institute, University of Pittsburgh, Cedars-Sinai Medical Center, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Memorial Sloan Kettering Cancer Center, Northwestern University, Wake Forest University Health Sciences, Wake Forest University, Harvard University
Language: English
Subfield: Epidemiology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W2599220830